Amid Huntington’s disease hopes and failures, Annexon targets new approach

There are no approved therapies for people with Huntington's disease, an inherited neurodegenerative disease that can unset in the 30s and 40s with jerky muscle movements and drastic changes in behavior.

Founded on innovation, Texas Medical Center continues to drive life sciences and biotech discovery in Houston

Micro food hall Local Kitchens adding second Roseville location

Bham approves $1.5M in construction costs for Michael’s location at museum

Portland’s Hottest ‘Hoods: Where the most homes sold during Q2 2018

Most Admired CEOs 2022: Craig A. Spencer, Arden Group

Tilton joins CBRE to help expand KC capital markets business

Board of Urban Redevelopment Authority expected to vote on new executive director

Largest 3D-printed house ever listed for sale in Long Island

Amid Huntington’s disease hopes and failures, Annexon targets new approach

Previous CDC approves omicron-targeting boosters. People could begin receiving the shots next week.

Next Former Pitt pediatric neurosurgeon to join WVU Medicine

firststargroup

Kotek touts $500M Oregon housing plan at Leadership Summit

Retirement plans see boost as states mandate IRAs and tax credits lower costs

Norton Healthcare data breach affected more than 2 million people

Houston-based cell therapy company FibroBiologics files to go public

Suggested Posts

Saving but not investing tips passed from parents to millennials, PNC study says

Ennis, Texas: Becoming the fastest-growing small community in DFW

Coral Gables office site could be redeveloped as mixed use

Delta Community Credit Union’s Jai Rogers: Align CSR proposals with company’s values

Fort Worth housing inventory is slipping. Here’s what that means in the coming months

Huffines Communities plans development spanning over 1,000 acres in Grand Prairie

MENU

FirstStar Group

More Stories

Oregon leads nation in rate of marijuana consumption